Form 4: Harvard Bioscience CFO Jennifer Cote Disposes of Shares to Cover Tax Obligations

Jennifer Cote, CFO of Harvard Bioscience, disposed of 5,687 shares of common stock on March 19, 2025, to satisfy tax withholding obligations related to vested restricted stock units.

Summary

• On March 19, 2025, Jennifer Cote, the Chief Financial Officer of Harvard Bioscience, disposed of 5,687 shares of common stock.
• The transaction was executed to cover tax withholding obligations associated with restricted stock units (RSUs) that vested on the same date.
• The price per share for the disposal was $0.6886.
• Following the transaction, Cote beneficially owns 159,019 shares of Harvard Bioscience common stock.
• This total includes various RSUs with different vesting schedules and performance-based conditions, as well as shares acquired through the Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a routine transaction. It doesn't inherently convey positive or negative sentiment.

Future Outlook

The document outlines future vesting schedules for RSUs held by the CFO, including performance-based vesting conditions, indicating potential future increases in share ownership if performance targets are met.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives. This filing indicates a standard practice of covering tax obligations related to equity compensation.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units (RSUs) that vest over time, similar to those held by Jennifer Cote.
• The practice of selling shares to cover tax obligations upon vesting is common among executives in publicly traded companies.
• Companies like Thermo Fisher Scientific and Agilent Technologies, which operate in related industries, also utilize RSUs as part of their executive compensation plans.

Stakeholder Impact

• The disposal of shares by the CFO could have a minor, short-term impact on the stock price, but is unlikely to significantly affect long-term shareholder value.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Harvard Bioscience, Jennifer Cote, CFO, Form 4, Share Disposal, Restricted Stock Units, Tax Withholding, Beneficial Ownership, HBIO, Employee Stock Purchase Plan